Overview
InsureMe is a digital-first insurance broker and aggregator, matching customers with quotes across partner insurers for motor, travel, life and health policies. It is a small, capital-light platform business, with a market capitalisation around LKR 3.65 billion, and monetises primarily via broking commissions rather than underwriting risk. The single most important recent shift is the stock’s sharp re-rating, leaving it on a premium multiple relative to listed insurance peers. That premium demands clear evidence of scalable growth and sustained margins for a broker of this size. Illiquidity also characterises trading, which can amplify price swings and complicate entry and exit for institutional investors, placing a higher bar on fundamentals and disclosures to maintain confidence.
Price performance
The share price rose 35.6% over three months, sharply outperforming a weak market as the ASPI fell 6.3%. Near term momentum is still positive, with a 1-week gain of 2.3%. At LKR 1,774, the stock trades well below its 52-week high of LKR 2,750 and above the LKR 1,285 low, sitting mid-range as investors digest the re-rating. Liquidity is extremely thin, with average 20-day volume of just 29 shares, so prints can be noisy and spreads wide. A reliable beta estimate is unavailable, but the recent divergence from the index underlines stock-specific forces rather than market co-movement.
Valuation
The shares are priced for strong growth at 46.3x trailing earnings and 15.0x book value. High capital efficiency is evident, with ROE of 35.7%, which helps explain some of the premium to peers because P/B should scale with ROE. Even so, the multiples stand far above sector medians of 13.22x P/E and 1.09x P/B, implying the market is banking on rapid scaling of commissions and durable margins. There is no dividend yield, so returns rely on earnings compounding and further re-rating. With a small equity base and early-stage scale, execution and consistency will need to validate these expectations.
News and sentiment
Coverage is thin: there were 0 material articles in the past 90 days, so the recent price strength has unfolded without fresh company-specific disclosures. We do not see confirmed corporate actions in the period, and there are no flagged events awaiting dates. In this context, sentiment is being set by trading flows rather than news catalysts, which raises the premium on the next set of results and on any updates about insurer partnerships, product expansion or monetisation levers. Until communication becomes more regular, investors must lean heavily on filed numbers to gauge momentum and durability of margins.
Financials
For the quarter to 30 Jun 2026, revenue was LKR 154.2 million and net profit LKR 21.4 million. Margins were healthy for a broker, with gross margin at 49.6%, operating margin at 19.5% and net margin at 13.9%. Year-ago comparisons are not available in the dataset, so we cannot assess margin trajectory yet. Below the line, finance costs, tax, associates and FX together reduced profit by LKR 8.7 million relative to operating profit, a manageable drag at this scale. The business model remains capital-light and fee-driven, which should support cash conversion, but the absence of disclosed year-on-year trends limits read-through on growth durability.
Risks
Liquidity is the immediate practical risk: trading is very thin, so price discovery can be erratic and exits costly. Valuation risk is elevated given the premium multiples; any slip in growth or margins could trigger a sharp de-rating. As an aggregator, InsureMe depends on partner insurers’ commission structures, underwriting appetites and service levels; shifts here can compress take-rates or conversion. Customer acquisition costs and digital execution are critical, with cybersecurity and platform uptime integral to trust. Sector-wide, interest-rate and FX settings influence insurers’ pricing and reinsurance costs, indirectly affecting broker volumes. Regulatory changes to distribution or disclosure for digital sales could alter economics.
Outlook
With no fresh disclosures, the next quarter’s print is the catalyst. Evidence of scaling would be revenue stepping above roughly LKR 160 million while holding net margin at or above 14%. Margin quality will be in focus: an operating margin sustained near 20% would support the premium; a slide toward the low teens would challenge it. Watch mix and partner breadth for signs of resilience across product lines, and any commentary on lead-generation costs. Strategic signals would include new insurer tie-ups, product additions, or a roadmap to dividends. Finally, any improvement in trading liquidity or disclosure cadence would lower the stock’s risk premium.